This week, 10 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Stemline Therapeutics, Inc. (STML) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). For more information, get Portfolio Grader’s complete analysis of STML stock.
This week, Pharmacyclics, Inc. (PCYC) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
Acorda Therapeutics, Inc. (ACOR) shows solid improvement this week. The company’s rating rises from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
This week, Northwest Biotherapeutics, Inc.’s (NWBO) ratings are up from a C last week to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
This week, Chimerix, Inc. (CMRX) pushes up from a B to an A rating. Trade volume fell markedly in the past week, standing at half of the previous rate. For more information, get Portfolio Grader’s complete analysis of CMRX stock.
Ophthotech Corp. (OPHT) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of OPHT stock.
BioMarin Pharmaceutical (BMRN) is seeing ratings go up from a C last week to a B this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Seattle Genetics, Inc. (SGEN) gets a higher grade this week, advancing from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
This is a strong week for Ambit Biosciences Corp. (AMBI). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
Amgen (AMGN) earns an A this week, jumping up from last week’s grade of B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
